Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

Calendar

18/08 Earnings release - Q2 2026

More about the company

Market Cap	6.73M 0 5.81M 5.46M 4.97M 9.34M 643M 9.49M 63.99M 25.02M 322M 25.26M 24.71M 1.07B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	6.73M 0 5.81M 5.46M 4.97M 9.34M 643M 9.49M 63.99M 25.02M 322M 25.26M 24.71M 1.07B	EV / Sales 2026 *	4.53x	EV / Sales 2027 *	2.59x
Free-Float	78.43%	Yield 2026 *	-	Yield 2027 *	-

09:21pm	Freightos Names Yaron Eldad as Chief Financial Officer	MT
27/07	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
11/07	L.I.A. Pure Capital Sends Letter to Evogene	CI
09/07	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
24/06	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
02/06	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
21/05	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/05	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
20/05	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
19/05	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
25/04	Evogene's Casterra unit eyes castor crop growth in Brazil	RE

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
19/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
30/07/21	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/12/20	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

08:33pm	Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation	AQ
14/08	Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation	PR
30/07	Evogene Schedules Second Quarter 2026 Financial Results Release	PR
22/07	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
08/07	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Evogene Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	6.73M
LONZA GROUP AG	+0.28%	-2.42%	+1.76%	+19.53%	48.42B
REVOLUTION MEDICINES, INC.	+0.72%	-0.70%	+460.88%	+581.30%	43.66B
BEONE MEDICINES AG	+3.67%	-0.23%	+8.13%	+80.67%	39.51B
IQVIA HOLDINGS INC.	-0.03%	-0.85%	+23.85%	+9.97%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	-1.64%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.33%	-2.06%	+26.35%	+126.36%	16.15B
EUROFINS SCIENTIFIC SE	-0.97%	-0.20%	+3.80%	+27.55%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.84%	+4.70%	+78.74%	+38.66%	13.37B
Average	+0.19%	-0.35%	+78.01%	+117.78%	29.24B
Weighted average by Cap.	+0.55%	-0.62%	+95.87%	+140.77%

	2026 *	2027 *
Net sales	1.48M 0 1.28M 1.2M 1.1M 2.06M 142M 2.09M 14.11M 5.52M 71.06M 5.57M 5.45M 236M	2.6M 0 2.25M 2.11M 1.92M 3.61M 249M 3.67M 24.73M 9.67M 124M 9.76M 9.55M 414M
Net income	-16.69M -0 -14.41M -13.54M -12.32M -23.16M -1.6B -23.54M -159M -62.05M -799M -62.65M -61.29M -2.66B	-13.92M -0 -12.02M -11.29M -10.27M -19.31M -1.33B -19.63M -132M -51.74M -666M -52.24M -51.11M -2.21B
Net Debt	-	-